Terms: = Lymphoma AND CCND1, BCL1, 595, ENSG00000110092, PRAD1, U21B31, D11S287E AND Treatment
143 results:
1. lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis.
Knauft J; Schenk T; Ernst T; Schnetzke U; Hochhaus A; La Rosée P; Birndt S
Leukemia; 2024 Feb; 38(2):235-249. PubMed ID: 38238443
[TBL] [Abstract] [Full Text] [Related]
2. Recent advances in genomics and therapeutics in mantle cell lymphoma.
Lu T; Zhang J; McCracken JM; Young KH
Cancer Treat Rev; 2024 Jan; 122():102651. PubMed ID: 37976759
[TBL] [Abstract] [Full Text] [Related]
3. Illuminating (HTLV-1)-induced adult T-cell leukemia/lymphoma transcriptomic signature: A systems virology approach.
Forghani-Ramandi MM; Mostafavi B; Bahavar A; Dehghankar M; Siami Z; Mozhgani SH
Virus Res; 2023 Dec; 338():199237. PubMed ID: 37832654
[TBL] [Abstract] [Full Text] [Related]
4. NFE2L2 and STAT3 Converge on Common Targets to Promote Survival of Primary lymphoma Cells.
Arena A; Di Crosta M; Gonnella R; Zarrella R; Romeo MA; Benedetti R; Gilardini Montani MS; Santarelli R; D'Orazi G; Cirone M
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511362
[TBL] [Abstract] [Full Text] [Related]
5. NOTCH Signaling in Mantle Cell lymphoma: Biological and Clinical Implications.
Deshotels L; Safa FM; Saba NS
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373427
[TBL] [Abstract] [Full Text] [Related]
6. Immunochemotherapy for life-threatening haematological malignancies in pregnancy: a systematic review of the literature and cross-sectional analysis of clinical trial eligibility.
Mills GS; Chadwick V; Tang C; Perram J; Anderson MA; Anazodo A; Kidson-Gerber G; Shand A; Lavee O; Withers B; Milliken S; Di Ciaccio PR; Hamad N
Lancet Haematol; 2023 Jun; 10(6):e458-e467. PubMed ID: 37263722
[TBL] [Abstract] [Full Text] [Related]
7. Utility of Measurable Residual Disease (MRD) Assessment in Mantle Cell lymphoma.
Wu S; Blombery P; Westerman D; Tam CS
Curr Treat Options Oncol; 2023 Aug; 24(8):929-947. PubMed ID: 37249800
[TBL] [Abstract] [Full Text] [Related]
8. Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy.
Burke JM; Liu N; Yu KS; Fanale MA; Surinach A; Flores C; Lisano J; Phillips T
Oncologist; 2023 Jun; 28(6):520-530. PubMed ID: 36971492
[TBL] [Abstract] [Full Text] [Related]
9. Repurposed Effect of
Elajami MK; Burton LP; Bahmad HF; Chaaya G; Schwartz M
Curr Oncol; 2022 Oct; 29(10):7552-7557. PubMed ID: 36290871
[TBL] [Abstract] [Full Text] [Related]
10. Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based Payment Arrangement.
Gye A; Goodall S; De Abreu Lourenco R
Pharmacoeconomics; 2023 Feb; 41(2):175-186. PubMed ID: 36266557
[TBL] [Abstract] [Full Text] [Related]
11. Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma.
LeBlanc FR; Hasanali ZS; Stuart A; Shimko S; Sharma K; Leshchenko VV; Parekh S; Fu H; Zhang Y; Martin MM; Kester M; Fox T; Liao J; Loughran TP; Evans J; Pu JJ; Spurgeon SE; Aladjem MI; Epner EM
Oncotarget; 2022; 13():986-1002. PubMed ID: 36093297
[TBL] [Abstract] [Full Text] [Related]
12. Clinicopathologic Features and treatment of CD10-Positive Mantle Cell lymphoma: A Case Report and Review of Literature.
Hino C; Pham B; Gray AL; Wang J; Castillo DR; Akhtari M; Liu Y
Pathol Oncol Res; 2022; 28():1610588. PubMed ID: 36091937
[TBL] [Abstract] [Full Text] [Related]
13. Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.
Freeman CL; Pararajalingam P; Jin L; Balasubramanian S; Jiang A; Xu W; Grau M; Zapukhlyak M; Boyle M; Hodkinson B; Schaffer M; Enny C; Deshpande S; Sun S; Vermeulen J; Morin RD; Scott DW; Lenz G
Leukemia; 2022 Oct; 36(10):2479-2487. PubMed ID: 35963941
[TBL] [Abstract] [Full Text] [Related]
14. [ALK-positive large B-cell lymphoma with EBV infection or cyclin D1 expression: a clinicopathological analysis of 3 cases].
Wu WN; Xiang CX; Ma DS; Liu GZ; Liu H
Zhonghua Bing Li Xue Za Zhi; 2022 Jun; 51(6):506-511. PubMed ID: 35673721
[No Abstract] [Full Text] [Related]
15. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.
Yi S; Yan Y; Jin M; Bhattacharya S; Wang Y; Wu Y; Yang L; Gine E; Clot G; Chen L; Yu Y; Zou D; Wang J; Phan AT; Cui R; Li F; Sun Q; Zhai Q; Wang T; Yu Z; Liu L; Liu W; Lyv R; Sui W; Huang W; Xiong W; Wang H; Li C; Xiao Z; Hao M; Wang J; Cheng T; Bea S; Herrera AF; Danilov A; Campo E; Ngo VN; Qiu L; Wang L
J Clin Invest; 2022 Feb; 132(3):. PubMed ID: 34882582
[TBL] [Abstract] [Full Text] [Related]
16. A Network Pharmacology-Based Study on Irritable Bowel Syndrome Prevention and treatment Utilizing Shenling Baizhu Powder.
Meng M; Bai C; Wan B; Zhao L; Li Z; Li D; Zhang S
Biomed Res Int; 2021; 2021():4579850. PubMed ID: 34859100
[TBL] [Abstract] [Full Text] [Related]
17. Chronic Lymphocytic Leukemia/Small Lymphocytic lymphoma With Secondary Acquisition of t(11;14)(q13;q32)/ccnd1-IGH: A Rare Variant Of Richter Transformation to Mantle Cell lymphoma.
Zhao Y; McCracken J; Rehder C; Wang E
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e310-e313. PubMed ID: 34840090
[TBL] [Abstract] [Full Text] [Related]
18. Mantle cell lymphoma: A clinical review of the changing treatment paradigms with the advent of novel therapies, and an insight into Indian data.
Radhakrishnan VS; Lokireddy P; Parihar M; Prakash PS; Menon H
Cancer Rep (Hoboken); 2022 Jul; 5(7):e1590. PubMed ID: 34821081
[TBL] [Abstract] [Full Text] [Related]
19. Ibrutinib With Rituximab in First-Line treatment of Older Patients With Mantle Cell lymphoma.
Jain P; Zhao S; Lee HJ; Hill HA; Ok CY; Kanagal-Shamanna R; Hagemeister FB; Fowler N; Fayad L; Yao Y; Liu Y; Moghrabi OB; Navsaria L; Feng L; Nogueras Gonzalez GM; Xu G; Thirumurthi S; Santos D; Iliescu C; Tang G; Medeiros LJ; Vega F; Avellaneda M; Badillo M; Flowers CR; Wang L; Wang ML
J Clin Oncol; 2022 Jan; 40(2):202-212. PubMed ID: 34797699
[TBL] [Abstract] [Full Text] [Related]
20. The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma.
Wang H; Zhang W; Yang J; Zhou K
Hematol Oncol; 2021 Dec; 39(5):605-615. PubMed ID: 34651869
[TBL] [Abstract] [Full Text] [Related]
[Next]
